Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741815 | 0.94 | FYN (0.36) | TSHRFYNALDH1A1GAAPDE5A | |
| SCHEMBL6742027 | 0.92 | TSHR (0.35) | TSHRFYNALDH1A1GAAPDE5A | |
| SCHEMBL6739659 | 0.91 | TSHR (0.43) | TSHRFYNGAAPDE5AS1PR4 | |
| SCHEMBL6745669 | 0.91 | TSHR (0.43) | TSHRFYNGAAPDE5AS1PR4 | |
| SCHEMBL6739562 | 0.91 | CHRM4 (0.37) | TSHRFYNALDH1A1GAAPDE5A | |
| SCHEMBL6745519 | 0.90 | APP (0.36) | TSHRALDH1A1GAAPDE5A | |
| SCHEMBL6740758 | 0.88 | KDM4E (0.36) | ALDH1A1GAA | |
| SCHEMBL6740895 | 0.88 | TSHR (0.34) | TSHRALDH1A1GAAPDE5A | |
| SCHEMBL6741029 | 0.88 | TSHR (0.34) | TSHRALDH1A1GAAPDE5A | |
| SCHEMBL6846143 | 0.87 | ALDH1A1 (0.33) | TSHRALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818642-B2 | CAMPYLOBACTER INFECTION TREATMENT | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040152714-A1 | Benzylaminopyrimidines | ALTANA PHARMA AG (DE) | 2004-08-05 | — | — | US | disclosed |
| EP-1395594-A1 | NEW BENZYLAMINOPYRIMIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094832-A1 | NEW BENZYLAMINOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152714-A1 | Benzylaminopyrimidines | DPYD, PGLS, TPMT | TSHR 2503/4885FYN 3430/4885ALDH1A1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.